Evidence map›Paper›PMID 38656354›Full record

ReviewMedical oncology (Northwood, London, England)2024

A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.

Salim Hussein Hassan, Mohammad Y Alshahrani, Raed Obaid Saleh, Bahira Abdulrazzaq Mohammed, Abhinav Kumar, Sami G Almalki, Adnan Taan Alkhafaji, Pallavi Ghildiyal, Ahmed Read Al-Tameemi, Ahmed Elawady

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 4 countries.

Salim Hussein HassanCommunity Health Department, Technical Institute of Karbala, AL-Furat Al-Awsat Technical University, Najaf, Iraq. inkr.salm@atu.edu.iq.
Mohammad Y AlshahraniDepartment of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia.
Raed Obaid SalehDepartment of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Iraq.
Bahira Abdulrazzaq MohammedDepartment of Technical Engineering, Al-Hadi University College, Baghdad, 10011, Iraq.
Abhinav KumarDepartment of Nuclear and Renewable Energy, Ural Federal University Named After the First President of Russia Boris Yeltsin, Ekaterinburg, 620002, Russia.
Sami G AlmalkiDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, 11952, Majmaah, Saudi Arabia.
Adnan Taan AlkhafajiCardiology Department, College of Medicine, Al-Ayen University, Dhi-Qar, Iraq.
Pallavi GhildiyalUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.
Ahmed Read Al-TameemiDepartment of Medical Engineering, AL-Nisour University College, Baghdad, Iraq.
Ahmed ElawadyCollege of Technical Engineering, The Islamic University, Najaf, Iraq.
Al-Ayen UniversityAl-Furat Al-Awsat Technical University · IQAl-Hadi University CollegeAl Maarif University College · IQAl-Nisour University College · IQKing Khalid University · SAMajmaah University · SAUniversity of Babylon · IQUral Federal University · RUUttaranchal University · IN

Funding

Deanship of Scientific Research, King Khalid University R.G.P.2/314/44
6 · The paper itself

Abstract

Chimeric Antigen Receptor (CAR) based therapies are becoming increasingly important in treating patients. CAR-T cells have been shown to be highly effective in the treatment of hematological malignancies. However, harmful therapeutic barriers have been identified, such as the potential for graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndrome (CRS). As a result, CAR NK-cell therapy is expected to be a new therapeutic option. NK cells act as cytotoxic lymphocytes, supporting the innate immune response against autoimmune diseases and cancer cells by precisely detecting and eliminating malignant cells. Genetic modification of these cells provides a dual approach to the treatment of AD and cancer. It can be used through both CAR-independent and CAR-dependent mechanisms. The use of CAR-based cell therapies has been successful in treating cancer patients, leading to further investigation of this innovative treatment for alternative diseases, including AD. The complementary roles of CAR T and CAR NK cells have stimulated exploration in this area. Our study examines the latest research on the therapeutic effectiveness of these cells in treating both cancer and ADs.

Indexed as

Autoimmune DiseasesImmunotherapy, AdoptiveKiller Cells, NaturalNeoplasmsReceptors, Chimeric AntigenAnimalsHumansReceptors, Chimeric AntigenCancer and autoimmune diseaseCAR NK-cellCAR T-cellImmunotherapy

Identifiers

PMID38656354
OpenAlexW4395078509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.